Anti-factor xa activity of standard and Japan-specific doses of rivaroxaban in thai patients with non-valvular atrial fibrillation

• المؤلفون الرئيسيون: Wanwarang Wongcharoen, Phongsathon Pacharasupa, Lalita Norasetthada, Siriluck Gunaparn, Arintaya Phrommintikul
• التنسيق: دورية
• منشور في: 2020
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087111274&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/70833
• المؤسسة: Chiang Mai University

© 2020 Japanese Circulation Society. All rights reserved. Background: Recommended rivaroxaban doses for stroke prevention in atrial fibrillation (SPAF) are 20 and 15 mg/day in patients with normal and reduced renal function, respectively, but lower doses (15 and 10 mg) have been tested and approved...